NasdaqGM - Nasdaq Real Time Price USD

TransMedics Group, Inc. (TMDX)

92.08 +2.83 (+3.17%)
At close: April 26 at 4:00 PM EDT
92.11 +0.03 (+0.03%)
After hours: April 26 at 7:47 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. Waleed H. Hassanein M.D. Founder, President, CEO & Director 1.82M 13.38M 1968
Mr. Stephen Gordon CFO, Treasurer & Secretary 909.62k 1.31M 1968
Mr. Nicholas Corcoran Senior Vice President of Supply Chain & Operations 812.07k -- 1983
Mr. Anil Ranganath Senior VP, General Counsel & Corporate Secretary 561.67k -- --
Dr. Tamer I. Khayal M.D. Chief Commercial Officer 900.11k 5.45M 1969
Mr. Mark Anderson Senior Director of Technology Development -- -- --
Ms. Susan Goodman Vice President of Human Resources -- -- --
Ms. Miriam C. Provost Ph.D. Vice President of Global Regulatory Affairs 535.93k 390.25k 1961

TransMedics Group, Inc.

200 Minuteman Road
Suite 302
Andover, MA 01810
United States
978 552 0900 https://www.transmedics.com
Sector: 
Healthcare
Industry: 
Medical Devices
Full Time Employees: 
584

Description

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

Corporate Governance

TransMedics Group, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 3. The pillar scores are Audit: 2; Board: 3; Shareholder Rights: 3; Compensation: 6.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

Apr 29, 2024 - May 03, 2024
TransMedics Group, Inc. Earnings Call

Related Tickers

INMD InMode Ltd.
17.14
+0.71%
 
SWAV Shockwave Medical, Inc.
330.00
+0.31%
 
NARI Inari Medical, Inc.
38.42
+0.92%
 
DXCM DexCom, Inc.
124.34
-9.91%
 
ALGN Align Technology, Inc.
309.02
-0.48%
 
INSP Inspire Medical Systems, Inc.
237.45
+2.79%
 
CLPT ClearPoint Neuro, Inc.
5.26
-0.94%
 
PODD Insulet Corporation
166.19
+1.23%
 
BSX Boston Scientific Corporation
73.17
-0.12%
 
OM Outset Medical, Inc.
2.4000
+0.84%